Jingda Zhang

Title: Innovations by Jingda Zhang in Crystalline Forms of Acalabrutinib

Introduction

Jingda Zhang is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of crystalline forms of Acalabrutinib. His work has led to advancements that may enhance the efficacy and stability of this important drug.

Latest Patents

Jingda Zhang holds 1 patent related to his innovative work. The patent focuses on crystalline forms of Acalabrutinib, which include several specific co-crystals. These forms are Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea. This invention aims to improve the properties of Acalabrutinib for better therapeutic outcomes.

Career Highlights

Jingda Zhang is currently associated with Apotex Inc., a leading global pharmaceutical company. His role at Apotex has allowed him to focus on innovative drug formulations and contribute to the company's mission of providing high-quality medications. His expertise in crystallography and pharmaceutical sciences has been instrumental in his career.

Collaborations

Jingda Zhang has collaborated with several professionals in his field, including Fabio E S Souza and Bahareh Khalili. These collaborations have fostered a productive environment for research and development, leading to significant advancements in pharmaceutical innovations.

Conclusion

Jingda Zhang's contributions to the field of pharmaceuticals, particularly through his patent on crystalline forms of Acalabrutinib, highlight his role as an influential inventor. His work not only enhances the understanding of drug formulations but also paves the way for future innovations in the industry.